Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATP4A | P20648 | 1/20 | 0.58 |
| ▸ | ATP4B | P51164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7142282 | 0.99 | RAB9A (0.58) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9298431 | 0.81 | ATP4A (0.63) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9297002 | 0.80 | ATP4A (0.59) | RAB9AMAPTNPC1ATP4AATP4B | |
| Bromide SCHEMBL9296510 | 0.80 | ATP4A (0.61) | RAB9AMAPTNPC1ATP4AATP4B | |
| SCHEMBL6313027 | 0.79 | RAB9A (0.56) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL2829791 | 0.77 | RAB9A (0.65) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL220846 | 0.76 | RAB9A (0.97) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.76 | MAPT (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL914552 | 0.76 | RAB9A (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL16653815 | 0.75 | RAB9A (1.00) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2020-05-07 | — | — | US | disclosed |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | VYOME THERAPEUTICS LIMITED (IN) | 2020-02-25 | — | — | US | disclosed |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME THERAPEUTICS LIMITED (IN) | 2018-09-20 | — | — | US | disclosed |
| EP-3328856-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | Vyome Biosciences Pvt. Ltd. (IN) | 2018-06-06 | — | — | EP | disclosed |
| CN-104540831-B | The difluoro dioxolanes aminobenzimidazole kinase inhibitor disorderly for treating cancer, autoimmune inflammation and CNS | 4SC探索有限责任公司 | 2017-11-07 | — | — | CN | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | disclosed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| EP-2867237-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC Discovery GmbH (DE) | 2015-05-06 | — | — | EP | disclosed |
| CN-104540831-A | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH | 2015-04-22 | — | — | CN | disclosed |
| WO-2014001464-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2014-01-03 | — | — | WO | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| EP-0074229-A1 | Triazole gastric anti-secretory agents | PFIZER INC. (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | RAB9A 1440/4885MAPT 86/4885NPC1 987/4885 |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CNKSR1, TYK2, ERBB2 | RAB9A 2636/4885MAPT 3006/4885NPC1 3777/4885 |
| US-20180265523-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | RAB9A 1807/4885MAPT 3826/4885NPC1 1232/4885 |
| US-20200140460-A1 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | CLPP, CFTR, ELANE | RAB9A 1807/4885MAPT 3826/4885NPC1 1232/4885 |
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | CLPP, CFTR, ELANE | RAB9A 1807/4885MAPT 3826/4885NPC1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.